title: Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion?: Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation.
authors.affiliation: Dept. of Stem Cell Transplantation and Cellular Therapy, 1515 Holcombe Blvd., Unit 423, Houston, TX 77030, United States. Electronic address: Bandersson@mdanderson.org.
authors.forename: Borje S
authors.initials: BS
authors.lastname: Andersson
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D019172:Transplantation Conditioning / Q000379:methods*; D014740:Vidarabine / Q000031:analogs & derivatives*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D014740:Vidarabine; D002066:Busulfan